

Causality between Diabetes and MN: Mendelian randomization and meta-analysis

1 **Zhihang Su^{1,+}, Ziqi Luo^{2,+}, Di Wu¹, Wen Liu¹, Wangyang Li¹, Zheng Yin¹, Rui Xue¹, Liling**
2 **Wu¹, Yuan Cheng¹, Qijun Wan^{*}**

3 ¹ Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of
4 Shenzhen University, Shenzhen, China

5 ² Department of Endocrinology, Shenzhen Second People's Hospital, the First Affiliated Hospital of
6 Shenzhen University, Shenzhen, China

7 *** Correspondence:**

8 Corresponding Author: Qijun Wan (Email: yiyan2224@sina.com)

9

10 **Keywords: Diabetes, Insulin use, Membranous nephropathy, Mendelian randomization, Meta-**
11 **analysis, Genome-wide association studies (GWAS).**

12 **Abstract**

13 **Background:**

14 Membranous nephropathy (MN) has not yet been fully elucidated regarding its relationship with
15 Type I and II Diabetes. This study aims to evaluate the causal effect of multiple types of diabetes and
16 MN by summarizing the evidence from the Mendelian randomization (MR) study.

17 **Methods:**

18 The statistical data for MN was obtained from a GWAS study encompassing 7,979 individuals.
19 Regarding diabetes, fasting glucose, fasting insulin, and HbA1C data, we accessed the UK-Biobank,
20 within family GWAS consortium, MAGIC, Finnish database, MRC-IEU, and Neale Lab, which
21 provided sample sizes ranging from 17,724 to 298,957. As a primary method in this MR analysis, we
22 employed the Inverse Variance Weighted (IVW), Weighted Median, Weighted mode, MR-Egger,
23 Mendelian randomization pleiotropy residual sum, and outlier (MR-PRESSO) and Leave-one-out
24 sensitivity test. Reverse MR analysis was utilized to investigate whether MN affects Diabetes. Meta-
25 analysis was applied to combine study-specific estimates.

26 **Results :**

27 It has been determined that type 2 diabetes, gestational diabetes, type 1 diabetes with or without
28 complications, maternal diabetes, and insulin use pose a risk to MN. Based on the genetic prediction,
29 fasting insulin, fasting blood glucose, and HbA1c levels were not associated with the risk of MN. No
30 heterogeneity, horizontal pleiotropy, or reverse causal relationships were found. The meta-analysis
31 results further validated the accuracy.

32 **Conclusions:**

33 The MR analysis revealed the association between MN and various subtypes of diabetes. This study
34 has provided a deeper understanding of the pathogenic mechanisms connecting MN and diabetes.

35 **1 Introduction**

36 Membranous nephropathy (MN), the most common etiology in adult nephrotic syndrome, is an
37 immune-related disease(1). Approximately 80% of patients cannot identify a specific cause and are
38 referred to as primary MN. The formation of immune complexes in the mesangial area, typically
39 comprising immunoglobulin G (IgG), associated antigens, and complement components, including
40 the membrane attack complex (MAC), results in substantial thickening of the glomerular capillary
41 walls(2). Immune dysregulation resulting from this immune conflict disrupts the structural integrity
42 of podocytes, leading to significant proteinuria. Spontaneous complete remission rates of untreated
43 MN have been reported to range from 20% to 30%, and advancements have been achieved in
44 utilising immunosuppressive drugs to manage MN. However, around 10% of patients with MN
45 eventually develop end-stage renal disease (ESRD), and within a 10-year timeframe, 40-50% of
46 individuals with nephrotic syndrome encounter kidney failure.

47 Diabetes is an increasingly severe global public health issue, with its prevalence increasing year by
48 year. As of 2019, approximately 463 million adults (one in ten) worldwide have diabetes, of which
49 half remain undiagnosed(3). In addition, diabetes in young people is also on the rise. Type 1 diabetes
50 in childhood and type 2 diabetes in adolescence are both increasing. The medical costs associated
51 with diabetes and its complications are incalculable(4). Diabetic nephropathy (DN) is a common
52 complication of diabetes. It has become a significant cause of chronic kidney disease (CKD) and end-
53 stage renal disease (ESRD) with the increasing prevalence of diabetes(5). In the past, the diagnosis of
54 diabetic nephropathy mainly relied on clinical diagnosis(6). With the development of renal biopsy
55 techniques, it has been found that many patients diagnosed clinically with DN may have non-diabetic
56 renal disease (NDRD)(7). This disease may exist alone or coexist with DN. Early detection of non-
57 diabetic renal disease (NDRD) has become critical in our clinical practice. Membranous nephropathy
58 (MN) is a common cause of primary glomerular disease in diabetic patients(8). DN and MN can
59 manifest as proteinuria and impaired renal function, which are difficult to distinguish without renal
60 biopsy(9). Several studies have found that compared with DN patients, NDRD or DN+NDRD
61 patients show significant improvement in proteinuria and renal function after receiving systemic
62 treatment with glucocorticoids, immunosuppressants, antihypertensives, and lipid-lowering
63 drugs(10). However, for DN patients, the use of steroids and other immunosuppressive drugs (used to
64 treat MN) can worsen glycemic control and increase the risk of infection in diabetic patients.
65 Although membranous nephropathy is a commonly occurring primary glomerular disease in non-
66 diabetic individuals, data on its natural progression, treatment, and outcomes in diabetic patients are
67 limited.

68 Previous magnetic resonance (MR) studies have firmly established a causal link between diabetes
69 and a range of systemic diseases, encompassing gastrointestinal disease, carcinoma psychiatric
70 disorders and so on(11–13). Nevertheless, a comprehensive overview of the association between
71 diabetes and MN remains elusive, hindering our comprehension of severe kidney diseases associated
72 with diabetes. Consequently, we conducted an MR analysis to evaluate the causal relationship
73 between diabetes phenotypes and MN, considering this challenge. MR is an analytical method to
74 infer causal relationships between exposures and outcomes(14). It utilizes instrumental variables,
75 which are single nucleotide polymorphisms (SNPs) identified from genome-wide association studies
76 (GWAS)(15). These SNPs are widely employed as instrumental variables (IVs) because their alleles
77 are randomly assigned and independent of confounding factors such as gender and age and are

78 unaffected by the outcome (e.g., the disease itself). Compared to traditional observational studies,
79 MR methods effectively address issues related to confounding factors and reverse causality. In this
80 study, we conducted MR analysis using phenotype data for diabetes phenotypes and MN obtained
81 from large-scale, openly accessible GWAS data.

82 **2 Data source**

83 We extracted the MR analysis data from the IEU Open GWAS database, which predominantly
84 comprises publicly available GWAS summary datasets(Figure 1). The statistical data for
85 membranous nephropathy (MN) was obtained from a GWAS study encompassing 7,979 individuals,
86 of which 2,150 were cases of primary MN and 5,829 served as controls(8). These individuals were
87 drawn from five European cohorts. The diagnosis of idiopathic membranous nephropathy cases was
88 confirmed through the gold standard diagnostic method of renal biopsy. Notably, secondary factors
89 such as patients with hepatitis B virus infection, drug-induced causes, and malignant tumours were
90 excluded from the analysis. Regarding diabetes, fasting glucose, fasting insulin and HbA1C data, we
91 accessed the UK-Biobank, Within family GWAS consortium, MAGIC, Finnish database, MRC-IEU,
92 and Neale Lab, which provided sample sizes ranging from 17,724 to 298,957(16–20). It is essential
93 to mention that all the databases above predominantly comprise individuals of European descent.

94 **3 Methods and materials**

95 **3.1 Selections of Instrument Variants**

96 The instrument variants (IVs) utilized in this MR study must adhere to three fundamental
97 assumptions (Figure 1):

98 (i) IVs should demonstrate strong associations with diabetes phenotypes. IVs with an F statistic less
99 than 10 [$F = (\beta / SE)^2$] are considered weak and therefore excluded.

100 (ii) IVs need to be independent. IVs associated with diabetes phenotypes were identified at a
101 genome-wide significance level ($P < 5 \times 10^{-8}$). IVs in high linkage disequilibrium (r^2) were identified
102 using a European reference panel (1000 gene project)(21), with exclusion criteria of $r^2 > 0.001$ or
103 within 10,000 kb.

104 (iii) IVs must be unrelated to the MN, influencing the outcome solely through indirect diabetes traits.
105 Additionally, potential confounding factors that could impact the association between diabetes traits
106 and MN were accounted for. These confounders include hepatitis B, hepatitis C, malignancies, and
107 medications (such as non-steroidal anti-inflammatory drugs, gold compounds, d-penicillamine,
108 bucillamine, and cyclosporine). Any IVs that could potentially act as confounders were removed.

109 **3.2 Mendelian randomization**

110 To ensure the robustness of our findings, we employed a range of methods in the MR analysis,
111 including Inverse variance weighted (IVW), MR Egger, Weighted median, Weighted mode,
112 Maximum likelihood, Constrained maximum likelihood (CML), and Penalized weighted median.
113 Among these approaches, IVW analysis emerges as the most effective MR analysis when genetic
114 instrument pleiotropy is absent, and the sample size is sufficiently large(22). IVW estimation
115 consistently provides reliable and close-to-true effect estimates. Consequently, we designated IVW as
116 the primary MR method. In instances where heterogeneity analysis yielded significant results ($P <$
117 0.05), we employed the IVW random effects model. The MR Egger method was utilized to examine

118 directional pleiotropy and causal associations, assuming the invalidity of all SNPs as instruments(23).
119 Weighted median analysis was employed when at least half of the SNPs had valid instruments(24).
120 CML evaluated population-wide overlap by maximizing the likelihood function, resulting in lower
121 standard errors. The Penalized weighted median estimator was also employed as a supplementary
122 method, modifying the standard weighted median MR. Causal estimate results from both primary and
123 supplementary MR analyses were visualized using scatter plots, while funnel plots were used to
124 depict the distribution of individual SNP effects. The MR analysis results are presented in the
125 accompanying table.

126 **3.3 Sensitivity analysis**

127 The sensitivity analysis comprises heterogeneity tests, pleiotropy tests, and leave-one-out analysis.
128 Our objective is to ensure that the significant results of the MR do not demonstrate heterogeneity or
129 horizontal pleiotropy in the sensitivity analysis. The heterogeneity of SNPs in each analysis is
130 assessed using Cochran's Q statistic, with $P > 0.05$ indicating the absence of heterogeneity in the MR
131 results(25). Horizontal pleiotropy may result in false positive findings when instrumental variables
132 are linked to multiple independent phenotypic effects. The MR Egger intercept test assesses
133 horizontal pleiotropy, with $P > 0.05$ indicating the absence of evidence for horizontal pleiotropy(23).
134 Leave-one-out analysis entails the sequential removal of instrumental variables for reanalysis to
135 evaluate the potential bias of individual SNPs on causal estimates. Since multiple databases are
136 utilized for specific subtypes of diabetes, we will acquire multiple MR results. Since multiple
137 databases are used for certain subtypes of diabetes, we will acquire multiple MR results. In cases
138 where two or more MR estimates for the same outcome derived from non-overlapping samples exist,
139 meta-analysis will be employed to derive a pooled estimate.

140 **3.4 Reverse Mendelian randomization analysis**

141 To avoid directional confounders, we will consider MN as the exposure and various subtypes of
142 diabetes as the outcomes for a subsequent round of MR analysis.

143 **3.5 Meta-analysis**

144 Due to the duplication of diabetes-related phenotype databases, we conducted MR analysis on
145 phenotypes with multiple databases and obtained various results. We then performed a meta-analysis
146 of the above results using a random-effects model(26).

147 **4 Results**

148 The MR analysis revealed significant associations between type 1, type 2, maternal, and gestational
149 diabetes and insulin use in diabetic patients with an elevated risk of MN(Figure 2 and 3, Supplement
150 Tables 1-4). We also found that the genetic prediction of fasting insulin, fasting blood glucose, and
151 HbA1c levels were not associated with the risk of MN(Supplement Tables 5-7). An increment of one
152 standard deviation (SD) in the genetic prediction of diverse diabetes-related phenotypes is associated
153 with a higher odds ratio (OR) for MN. The scatter plots depict the causal relationships and effect
154 sizes for each MR method. The funnel plots exhibit a well-balanced distribution of SNP effects.
155 Leave-one-out analysis identified no influential outliers impacting the final estimates, and the genetic
156 prediction-based causal effects of distinct diabetes subtypes on MN remained consistent with the
157 initial MR analysis even after sequentially removing individual SNPs. This indicates the stability and
158 robustness of our MR study. No evidence of horizontal pleiotropy or heterogeneity was observed (P
159 > 0.05), suggesting that other potential confounding factors are unlikely to introduce bias in our MR

160 study. In the reverse MR analysis, we did not find any evidence of reverse causality(Supplement
161 Table 8). The meta-analysis results of diverse phenotypes across multiple databases, employing a
162 random-effects model, exhibited statistical significance across the board, corroborating our MR
163 analysis findings. This provides further confirmation of the potential heightened risk of MN
164 associated with various diabetes-related phenotypes.

165 **5 Discussion**

166 The causal relationship between diabetes and MN remains a complex and multifaceted subject. In
167 recent years, the advancement of medical research has led to a gradual recognition of the intimate
168 association between diabetes and kidney diseases, particularly MN. This article aims to delve deeply
169 into the causal link between diabetes and MN, aiming to enhance public awareness and
170 comprehension of these diseases. This study marks the first attempt to integrate GWAS data from
171 extensive cohorts, utilizing multi-sample MR analysis and meta-analysis to assess the causal
172 relationship between various diabetes-related phenotypes and MN. Based on gene prediction, our
173 findings ultimately revealed that type 1 diabetes, type 2 diabetes, gestational diabetes, and insulin use
174 in diabetic patients in diabetic patients were significantly associated with an elevated risk of MN.
175 Sensitivity analysis further corroborated the positive causal relationship between these phenotypes
176 and MN.

177 Diabetes is a metabolic disease marked by persistently high blood glucose levels, potentially linked
178 to genetic predisposition, environmental factors, autoimmune responses, and other contributing
179 elements. MN, on the other hand, is a glomerular disorder associated with immune complexes. Its
180 primary manifestation is the deposition of these immune complexes on the epithelial side of the
181 glomerular capillary wall, often accompanied by widespread thickening of the basement membrane.

182 Our study revealed a positive correlation between MN and various diabetes types, including type 1,
183 type 2, gestational diabetes, and insulin usage among diabetes patients. Furthermore, Mendelian
184 randomization studies provide evidence for a causal linkage between genetic predisposition to
185 diabetes and an elevated risk of MN. However, our analysis indicated that genetically predicted
186 levels of fasting insulin, fasting glucose, and glycosylated hemoglobin did not correlate with the risk
187 of MN, suggesting that the association between diabetes subtypes and MN is not primarily mediated
188 by glucose dysregulation. Discovering a link between impaired glucose homeostasis and
189 gastrointestinal diseases holds potential clinical significance. This suggests that apart from managing
190 type 2 diabetes, pharmacological or lifestyle interventions aimed at decreasing circulating glucose
191 levels and fasting insulin levels could potentially contribute to preventing gastrointestinal diseases.

192 Numerous studies have consistently demonstrated that diabetes mellitus serves as a primary etiology
193 of kidney disease. Among patients diagnosed with diabetes, approximately 30% to 40% develop
194 kidney disease, with MN being a notable manifestation. However, our analysis indicated that the
195 association between diabetes and MN might not be mediated by glycemic dysregulation but rather by
196 other pathophysiological mechanisms. For instance, the immune system function of diabetic patients
197 may be compromised, leading to the deposition of immune complexes on the epithelial side of the
198 glomerular capillary wall, thereby precipitating MN(27). In addition, the incidence of insulin
199 resistance (IR) is continuously increasing in T1DM, T2DM, and gestational diabetes, especially in
200 overweight individuals and patients treated with insulin(28). IR can activate the complement system
201 to induce membranous nephropathy (29). On the other hand, diabetes can cause metabolic disorders
202 such as glucose, protein, fat, water, and electrolytes, promoting inflammation. Lipid accumulation
203 can damage podocytes (a structure and function crucial for maintaining the glomerular filtration

204 barrier of the glomerulus) and induce podocyte degeneration and foot process effacement(30).
205 Podocyte apoptosis is a critical process in the development of MN (30). Moreover, chronic
206 inflammation, including C-reactive protein, mononuclear chemotactic protein-1, interleukin 8, etc,
207 caused by diabetes can stimulate the body to secrete various inflammatory factors, exacerbating
208 kidney damage and glomerular sclerosis(31).

209 The causal link between diabetes and MN is well-established, yet the mechanism underlying this
210 relationship remains elusive. Current research has yet to fully elucidate the intricate pathways
211 through which diabetes triggers the entire process of MN, leaving this area ripe for further
212 exploration.

213 It is crucial to acknowledge that, according to genetic predictions, MN does not elevate the risk of
214 various diabetes types. Although MN may result in impaired renal function, it is not directly
215 implicated in the onset of diabetes. Instead, the occurrence of diabetes is influenced by a multitude of
216 factors, including heredity, environmental conditions, and autoimmunity. In contrast, MN primarily
217 represents a kidney disease that may be induced by diabetes. Consequently, for diabetic patients, the
218 prevention and management of MN are paramount. The risk of MN can be significantly mitigated by
219 regulating key parameters such as blood sugar, blood pressure, and blood lipids. Furthermore, for
220 patients who have already developed MN, it is imperative to adopt proactive treatment strategies to
221 decelerate the progression of the disease and safeguard renal function.

222 This study exhibits numerous strengths. Chief among them is the utilization of the MR methodology,
223 which significantly mitigates the potential for confounding and reverse causality biases. By
224 leveraging summary-level data from extensive genetic studies conducted in European populations,
225 our findings are unlikely to be skewed by population structure biases. Furthermore, estimating these
226 associations across independent data sources and their subsequent combination through meta-analysis
227 enhances the statistical power and the robustness of our research outcomes.

228 We must also acknowledge several limitations. Firstly, given that this is a non-linear MR analysis,
229 we cannot assess the non-linear association between diabetes and MN using aggregate-level data.
230 Moreover, we cannot discount the possibility that diabetes-related SNPs may affect MN through
231 alternative causal pathways. Notably, while additional MR analysis results, such as Weighted
232 median, Weighted mode, and MR-Egger, no longer exhibit statistically significant associations
233 observed in the primary analysis, this could be attributed to a reduction in method efficacy.
234 Nevertheless, we rely on IVW, the primary MR method, to observe the direction of these
235 associations, thus supporting the consistency of our findings. Additionally, sensitivity analysis was
236 conducted to validate the consistency of our results further, revealing that our findings are mainly
237 unaffected by heterogeneity and horizontal pleiotropy. Secondly, if the dichotomy of continuous risk
238 factors primarily defines diabetes, the MR analysis of diabetes as an exposed binary phenotype may
239 introduce biases due to the exclusion of restrictive assumptions. However, it is essential to note that
240 the threshold of continuous biomarkers does not solely define diabetes; it can also be determined by
241 ICD codes, drug usage, self-reports, or the threshold of HbA1c and blood glucose levels, as
242 employed in this study. Thirdly, our findings reveal no significant impact of fasting blood glucose,
243 fasting insulin, and HbA1c levels on MN. This observation suggests that the association between
244 diabetes mellitus of various types and MN is not primarily mediated by glucose dysregulation or
245 insulin resistance. Notably, most patients in our study had a long-standing diagnosis of diabetes
246 symptoms. These markers alone are clinically inadequate to assess pancreatic function, necessitating
247 further evaluation. Consequently, our data imply that diabetes-induced MN may have alternative
248 underlying mechanisms. Fourth, despite these findings, the odds ratio (OR) obtained from our MR

249 analysis of diabetes remains unexplained by the direct exposure unit, as previously reported in
250 studies. This limitation may hinder directly comparing our research outcomes with the magnitude
251 reported in observational studies. Fifth, SNPs related to diabetes were sourced from the general
252 population, whereas SNPs about blood glucose traits were derived from a population free of diabetes
253 diagnosis. Consequently, even if diabetic patients are included in the outcome data, the extrapolation
254 of the identified blood glucose traits to the entire population or specifically to diabetic patients
255 remains to be validated in future investigations. Sixth, the exclusive inclusion of European
256 populations in this study restricts the generality of the findings to other ethnic groups, such as those
257 in Asia and Africa. Seventh, discrepancies between genetic scoring and clinical diagnosis of diabetes
258 may give rise to potential misclassification of cases.

259 In our study, we observed a correlation between the genetic predisposition to diverse forms of
260 diabetes and an elevated risk of MN. Notably, fasting blood glucose levels, fasting insulin
261 concentrations, and HbA1c markers did not significantly influence the risk of MN. Furthermore,
262 diabetes appears to be a contributory factor in the emergence and progression of MN, which serves as
263 a manifestation of diabetic kidney disease. The profound comprehension and exploration of this
264 intricate relationship hold immense importance in preventing and managing diabetes and its
265 associated complications. Additionally, enhancing public knowledge and understanding regarding
266 these diseases is paramount to improving the overall health of individuals. It underscores the vital
267 role of early screening and renal disease prevention among diabetic patients.

268 **6 Conflict of Interest**

269 No conflict of interest.

270 **7 Funding**

271 Shenzhen Key Medical Discipline Construction Fund (SZXK009) and Shenzhen Sanming project
272 (SZSM202211013).

273 **8 Acknowledgments**

274 Thank you to all the contributors of the publicly available databases used in this study.

275 **9 Data Availability Statement**

276 All data are uploaded as supplementary materials.

277 **10 Reference styles**

278 1. Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol CJASN. 2017 Jun
279 7;12(6):983–97.

280 2. Ronco P, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V, et al. Membranous nephropathy.
281 Nat Rev Dis Primer. 2021 Sep 30;7(1):69.

282 3. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF
283 Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes
284 Res Clin Pract. 2018 Apr;138:271–81.

- 285 4. Tuttle KR, Jones CR, Daratha KB, Koyama AK, Nicholas SB, Alicic RZ, et al. Incidence of
286 Chronic Kidney Disease among Adults with Diabetes, 2015-2020. *N Engl J Med*. 2022 Oct
287 13;387(15):1430–1.
- 288 5. Ritz E, Rychlík I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical
289 catastrophe of worldwide dimensions. *Am J Kidney Dis Off J Natl Kidney Found*. 1999
290 Nov;34(5):795–808.
- 291 6. Liew A, Bavanandan S, Prasad N, Wong MG, Chang JM, Eiam-Ong S, et al. Asian Pacific
292 Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease - An Executive
293 Summary. *Nephrol Carlton Vic*. 2020 Nov;25(11):809–17.
- 294 7. Huang F, Yang Q, Chen L, Tang S, Liu W, Yu X. Renal pathological change in patients with
295 type 2 diabetes is not always diabetic nephropathy: a report of 52 cases. *Clin Nephrol*. 2007
296 May;67(5):293–7.
- 297 8. Xie J, Liu L, Mladkova N, Li Y, Ren H, Wang W, et al. The genetic architecture of
298 membranous nephropathy and its potential to improve non-invasive diagnosis. *Nat Commun*. 2020
299 Mar 30;11(1):1600.
- 300 9. Zhang W, Liu X, Dong Z, Wang Q, Pei Z, Chen Y, et al. New Diagnostic Model for the
301 Differentiation of Diabetic Nephropathy From Non-Diabetic Nephropathy in Chinese Patients. *Front*
302 *Endocrinol*. 2022;13:913021.
- 303 10. Radhakrishnan Y, Zand L, Sethi S, Fervenza FC. Membranous nephropathy treatment
304 standard. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc*. 2024 Feb
305 28;39(3):403–13.
- 306 11. Chen J, Yuan S, Fu T, Ruan X, Qiao J, Wang X, et al. Gastrointestinal Consequences of Type
307 2 Diabetes Mellitus and Impaired Glycemic Homeostasis: A Mendelian Randomization Study.
308 *Diabetes Care*. 2023 Feb 17;46(4):828–35.
- 309 12. Goto A, Yamaji T, Sawada N, Momozawa Y, Kamatani Y, Kubo M, et al. Diabetes and
310 cancer risk: A Mendelian randomization study. *Int J Cancer*. 2020 Feb 1;146(3):712–9.
- 311 13. Tao H, Fan S, Zhu T, You L, Zheng D, Yan L, et al. Psychiatric disorders and Type 2
312 diabetes mellitus: A bidirectional Mendelian randomization. *Eur J Clin Invest*. 2023
313 Mar;53(3):e13893.
- 314 14. Lin J, Zhou J, Xu Y. Potential drug targets for multiple sclerosis identified through Mendelian
315 randomization analysis. *Brain J Neurol*. 2023 Aug 1;146(8):3364–72.
- 316 15. Su Z, Wan Q. Potential therapeutic targets for Membranous Nephropathy: proteome-wide
317 Mendelian randomization and colocalization analysis. *Front Immunol*. 2024 Feb 21;15:1342912.
- 318 16. Manning AK, Hivert MF, Scott RA, Grimsby JL, Bouatia-Naji N, Chen H, et al. A genome-
319 wide approach accounting for body mass index identifies genetic variants influencing fasting
320 glycemic traits and insulin resistance. *Nat Genet*. 2012 May 13;44(6):659–69.

- 321 17. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, et al. Large-scale
322 association analyses identify new loci influencing glycemic traits and provide insight into the
323 underlying biological pathways. *Nat Genet.* 2012 Sep;44(9):991–1005.
- 324 18. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New
325 genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat*
326 *Genet.* 2010 Feb;42(2):105–16.
- 327 19. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, et al. Common variants at 10
328 genomic loci influence hemoglobin A_{1c}(C) levels via glycemic and nonglycemic pathways. *Diabetes.*
329 2010 Dec;59(12):3229–39.
- 330 20. Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars N, Benner C, Aguirre M, et al. Genetics of
331 35 blood and urine biomarkers in the UK Biobank. *Nat Genet.* 2021 Feb;53(2):185–94.
- 332 21. Byrska-Bishop M, Evani US, Zhao X, Basile AO, Abel HJ, Regier AA, et al. High-coverage
333 whole-genome sequencing of the expanded 1000 Genomes Project cohort including 602 trios. *Cell.*
334 2022 Sep 1;185(18):3426–3440.e19.
- 335 22. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG, EPIC- InterAct
336 Consortium. Using published data in Mendelian randomization: a blueprint for efficient identification
337 of causal risk factors. *Eur J Epidemiol.* 2015 Jul;30(7):543–52.
- 338 23. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments:
339 effect estimation and bias detection through Egger regression. *Int J Epidemiol.* 2015 Apr;44(2):512–
340 25.
- 341 24. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian
342 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet*
343 *Epidemiol.* 2016 May;40(4):304–14.
- 344 25. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple
345 genetic variants using summarized data. *Genet Epidemiol.* 2013 Nov;37(7):658–65.
- 346 26. Xu S, Li X, Zhang S, Qi C, Zhang Z, Ma R, et al. Oxidative stress gene expression, DNA
347 methylation, and gut microbiota interaction trigger Crohn’s disease: a multi-omics Mendelian
348 randomization study. *BMC Med.* 2023 May 11;21(1):179.
- 349 27. Zhou T, Hu Z, Yang S, Sun L, Yu Z, Wang G. Role of Adaptive and Innate Immunity in
350 Type 2 Diabetes Mellitus. *J Diabetes Res.* 2018;2018:7457269.
- 351 28. Petrelli A, Giovenzana A, Insalaco V, Phillips BE, Pietropaolo M, Giannoukakis N.
352 Autoimmune Inflammation and Insulin Resistance: Hallmarks So Far and Yet So Close to Explain
353 Diabetes Endotypes. *Curr Diab Rep.* 2021 Dec 13;21(12):54.
- 354 29. Xin Y, Hertle E, van der Kallen CJH, Schalkwijk CG, Stehouwer CDA, van Greevenbroek
355 MMJ. Complement C3 and C4, but not their regulators or activated products, are associated with
356 incident metabolic syndrome: the CODAM study. *Endocrine.* 2018 Dec;62(3):617–27.

357 30. Sun Y, Cui S, Hou Y, Yi F. The Updates of Podocyte Lipid Metabolism in Proteinuric
358 Kidney Disease. *Kidney Dis Basel Switz.* 2021 Nov;7(6):438–51.

359 31. Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular Biological and Clinical
360 Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with
361 Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease. *Int J Mol Sci.* 2021 Aug
362 26;22(17):9221.

363


364 Figure legends

365 Figure 1: The flowchart demonstrates the experimental design of this study.

366 Figure 2: The forest plot shows the results of the MR analysis. OR: odds ratio, IVW: Inverse variance
367 weighted, CI: confidence interval

368 Figure 3: meta-analysis results

ID	Exposure	No.of SNP	Method	OR(95% CI)	P
finn-b-O15_PREG_DM	Diabetes mellitus in pregnancy	2	IVW	1.54 (1.05 to 2.28)	0.029
finn-b-GEST_DIABETES	Gestational diabetes	2	IVW	1.47 (1.03 to 2.10)	0.035
ukb-b-16451	Gestational diabetes	17	IVW	46.06 (1.03 to 2050.78)	0.048
ukb-a-491	Insulin using	2	IVW	12172867600.00 (358.35 to 41400000000000000.00)	0.009
ukb-b-7350	Insulin using	3	IVW	37966774513.00 (2166.45 to 66500000000000000.00)	0.004
ukb-a-74	diabetes	25	IVW	77.28 (1.37 to 4343.59)	0.034
finn-b-E4_DM1	Type 1 diabetes	6	IVW	1.21 (1.01 to 1.45)	0.036
finn-b-E4_DM1NASCOMP	Type 1 diabetes	6	IVW	1.24 (1.05 to 1.46)	0.010
finn-b-E4_DM1NOCOMP	Type 1 diabetes	10	IVW	1.23 (1.08 to 1.39)	0.002
finn-b-T1D_WIDE	Type 1 diabetes	8	IVW	1.28 (1.09 to 1.50)	0.002
finn-b-T1D_WIDE1	Type 1 diabetes	8	IVW	1.28 (1.10 to 1.48)	0.001
ebi-a-GCST007515	Type 2 diabetes	56	IVW	1.27 (1.03 to 1.56)	0.023
ebi-a-GCST007517	Type 2 diabetes	47	IVW	1.30 (1.06 to 1.59)	0.011



Exposure	Source	Cases	Noncases	Odds Ratio	OR [95%-CI]	P
Gestational diabetes	finn-b-015_PREG_DM	6,033	110,330		1.54 [1.05, 2.28]	0.03
Gestational diabetes	finn-b-GEST_DIABETES	5,687	117,892		1.47 [1.03, 2.10]	0.04
Fixed effect model					1.50 [1.15, 1.96]	
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = .85$						
Test for overall effect: $z = 3.03$ ($p < .01$)				0.438282594369946		

Exposure	Source	Cases	Noncases	Odds Ratio	OR [95%-CI]	P
Type 1 diabetes	finn-b-E4_DM1	5,928	183,185		1.21 [1.01, 1.45]	0.04
Type 1 diabetes	finn-b-E4_DM1NASCOMP	3,416	183,185		1.24 [1.05, 1.46]	0.01
Type 1 diabetes	finn-b-E4_DM1NOCOMP	4,918	183,185		1.23 [1.08, 1.39]	0.00
Type 1 diabetes	finn-b-T1D_WIDE	6,729	182,573		1.28 [1.09, 1.50]	0.00
Type 1 diabetes	finn-b-T1D_WIDE1	4,849	180,722		1.28 [1.10, 1.48]	0.00
Fixed effect model					1.25 [1.16, 1.34]	
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = .98$						
Test for overall effect: $z = 6.34$ ($p < .01$)				0.664945512353605		

Exposure	Source	Cases	Noncases	Odds Ratio	OR [95%-CI]	P
Type 2 diabetes	ebi-a-GCST007515	48,286	250,671		1.27 [1.03, 1.56]	0.02
Type 2 diabetes	ebi-a-GCST007517	48,286	250,671		1.30 [1.06, 1.59]	0.01
Fixed effect model					1.28 [1.11, 1.48]	
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = .88$						
Test for overall effect: $z = 3.41$ ($p < .01$)				0.629895980324562		

Exposure	Source	Cases	Noncases	Odds Ratio	OR [95%-CI]	P
Insulin using	ukb-a-491	2,116	152,586		12172867600.00 [358.46, 413376428529543168.00]	0.01
Insulin using	ukb-b-7350	2,891	206,747		37966774513.00 [2167.11, 665159099646693504.00]	0.00
Fixed effect model					21978873521.81 [132252.74, 3652634069642065.00]	
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = .93$						
Test for overall effect: $z = 3.88$ ($p < .01$)				1.50339971373941e-18	0.1	665159099646693504